Developing allogeneic CAR-Tregs: an interview with Sangamo Therapeutics

Written by RegMedNet

In this interview, Jason Fontenot, SVP, Head of Cell Therapy, Sangamo Therapeutics, Inc. (WA, USA), discusses the challenges in producing therapeutic CAR-Treg cells and the opportunities presented by a new partnership with UK-based Mogrify. Could you introduce yourself and tell us about your role? I am the Head of Cell Therapy at Sangamo Therapeutics. I lead the cell therapy efforts at Sangamo including the CAR-Treg portfolio, the Sangamo collaboration with Kite/Gilead (CA, USA) to develop next generation T and NK cell therapies for oncology and other early-stage cell therapy programs. I am a T-cell immunologist by training and my previous...

To view this content, please register now for access

It's completely free